Medicenna announces the results of the General Meeting of Shareholders

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results at the Company’s annual meeting of shareholders held today, December 26 September 2024 (“Meeting”).

Medicenna is pleased to announce that all candidates listed in its Management Information Circular dated August 14, 2024 (the “Circular”) have been elected as directors. Detailed voting results are presented below:

	Nominee	Votes in favour		% of votes for		Votes against		% of votes against
	Doctor Fahar Merchant	26 237 107		99.44%		148557		0.56%
	Mr. Albert Beraldo	26,325,950		99.77%		59714		0.23%
	Dr. John (Jack) Geltosky	26,190,452		99.26%		195212		0.74%
	Mrs. Karen Dawes	26,228,732		99.41%		156,932		0.59%
	Dr. John H. Sampson	20,428,706		77.42%		5,956,958		22.58%
	Mr. Karim Lalji	26 314 082		99.73%		71582		0.27%

Medicenna shareholders also voted to elect MNP LLP as the Company’s auditor.

An aggregate of 45.89% of the Company’s issued and outstanding common shares were represented at the Meeting in person and by proxy.

More information about the transactions discussed at the Meeting can be found in the Circular available on SEDAR+ at www.sedarplus.ca. A report on the voting results will also be posted on SEDAR+.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company focused on developing new, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class enhanced superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with greater affinity for CD122 (IL-2 receptor beta) and no binding to CD25 (IL-2 receptor alpha), thereby preferentially stimulating the cancer-killing effector cells T and NK cells. Medicenna’s Bizaxofusp (formerly MDNA55) has been studied in 5 clinical trials involving more than 130 patients, including a Phase 2b study in recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has been granted FastTrack and orphan drug designation by the FDA and FDA/EMA, respectively. Medicenna’s early-stage IL-2/IL-15 superantagonists with high affinity for IL-2β from the MDNA209 platform are being evaluated as potential therapies for autoimmune and graft-versus-host diseases. Medicenna’s early-stage BiSKIT (Bifunction SuperKine ImmunoTherapies) and T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.

For more information, visit the website www.medicenna.comand follow us further Twitter AND LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the Company’s future operations, estimates, plans, strategic ambitions, activities and partnership opportunities, objectives, expectations, opinions, forecasts, projections, guidance, prospects or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potential”, “ambiguous” and similar expressions and are subject to risk and uncertainty. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in its most recent Annual Information Form and in other documents filed from time to time by the Company with the applicable securities regulatory authorities in Canada.

The reader is cautioned that the assumptions used in preparing any forward-looking information may prove to be incorrect. Events or circumstances could cause actual results to differ materially from those anticipated as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date they are made and, except as required by law, we have no intention, and assume no obligation, to publicly update or revise any forward-looking statements contained herein.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this new version.

Further information and contact details for investors/media:

Christina Cameron
Investor Relations, Medicenna Therapeutics
(647) 953-0673
[email protected]